Loading
NASDAQHealthcareBiotechnology
Latest quote
$3.385
−$0.085 · -2.45%
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
Regular session
$3.385
−$0.085 · -2.45%
Regular session · ET · Market data may be delayed.
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
Day range
Current $3.385
52-week range
Current $3.385
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
27
Expensive
Sentiment
43
Mixed
Risk
63
High Risk
Momentum
73
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
Day range
Current $3.385
52-week range
Current $3.385
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.23M USD | — | — | — | — |
| Cost of goods sold | 505K USD | 5K USD | 5K USD | 4K USD | 2K USD |
| Gross profit | 720K USD | −5K USD | −5K USD | −4K USD | −2K USD |
| Research and development | 3.78M USD | 6.2M USD | 13.37M USD | 17.03M USD | 20.26M USD |
| Selling, general, and administrative | 13.06M USD | 13.5M USD | 14.21M USD | 27.3M USD | 74.94M USD |
| Operating expenses | 16.94M USD | 19.7M USD | 27.58M USD | 44.33M USD | 95.2M USD |
| Interest income | 12K USD | 44K USD | 494K USD | 249K USD | 18 USD |
| Interest expense | 671K USD | 1.08M USD | 120K USD | — | 18K USD |
| Depreciation and amortization | 143K USD | 5K USD | 5K USD | 4K USD | 2K USD |
| Operating income | −16.22M USD | −19.7M USD | −27.59M USD | −44.34M USD | −95.2M USD |
| Net income | −28.62M USD | −25.13M USD | −30.15M USD | −39.75M USD | −93.06M USD |
Company facts updated Sep 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Apr 2, 2024 | 1:10 | — | — |
Effective Apr 2, 2024
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
AdvisorShares Psychedelics ETFPSIL
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
